FDA OFFICES OF SUPPLEMENTAL APPROVALS WOULD BE ESTABLISHED BY AMENDED KASSEBAUM BILL; "MEDGUIDE" WOULD BE BLOCKED BY COATS AMENDMENT
Executive Summary
FDA would be required to establish offices of supplemental approval in each of its centers under the version of Sen. Kassebaum's (R-Kan.) FDA reform bill that emerged from committee mark-up March 28. The provision is part of an amendment promoting the submission and approval of NDA supplements that was introduced by Sen. Kennedy (D-Mass.) and approved on a voice vote.
You may also be interested in...
US Patient Medical Information Rule: Will It Be Delayed Again?
FDA originally proposed mandatory patient labeling in 1980 only to have the rule withdrawn by the incoming Reagan Administration; thirty-five years later, US agency is finalizing a proposed rule on the same topic. Will history repeat itself?
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials